Oral bioavailability and pharmacokinetics of DRF-4367, a new cox-2 inhibitor in rats

  title={Oral bioavailability and pharmacokinetics of DRF-4367, a new cox-2 inhibitor in rats},
  author={M. Ramesh and R. Mamidi and Kota Jagannath and S. K. Singh and K. S. Rao and Y. K. Rao and Casturi Seshagirirao and R. Rajagopalan and N. Srinivas},
  journal={European Journal of Drug Metabolism and Pharmacokinetics},
  • M. Ramesh, R. Mamidi, +6 authors N. Srinivas
  • Published 2010
  • Chemistry, Medicine
  • European Journal of Drug Metabolism and Pharmacokinetics
  • SummaryThe pharmacokinetic characterization of DRF-4367 (a new diaryl pyrazole derivative), a potent selective COX-2 inhibitor was performed in Wistar rats. In the first study, a single dose of 2, 5, 10, 30 or 100 mg/kg DRF-4367 was given orally to rats for investigating the dose proportionality and/or linearity in the pharmacokinetics. In the second study, a single intravenous bolus dose of DRF-4367 was given at a dose of 10 mg/kg to calculate the absolute oral bioavailability, clearance and… CONTINUE READING
    1 Citations

    Figures, Tables, and Topics from this paper


    Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats
    • 28
    Gastrointestinal effects of COX-2 inhibitors.
    • 27
    Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.
    • 1,454
    • PDF
    Cyclooxygenase inhibitors--current status and future prospects.
    • 583
    The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
    • 2,411
    Cox-2-selective inhibitors: the new super aspirins.
    • 239
    • PDF
    Design, Synthesis and Biological Evaluation of 2Substituted Benzene sulphonamide Containing Novel Classof 1,5-Diaryl Pyrazoles as Cyclooxy -genase-2 Inhibitors
    • J. Med. Chern. submitted
    • 2002
    The effect of celecoxib, acyclooxygenase-2 inhibitor, in familial adenomatous polyposis
    • New Eng J Med
    • 2000